HelbertRondon-Berrios United StatesUniversity of Pittsburgh School of Medicine

HelbertRondon-Berrios
Dr. Rondon-Berrios is a Professor of Medicine in the Renal-Electrolyte Division at the University of Pittsburgh School of Medicine where he also serve as the Program Director of the Nephrology Fellowship Training Program. Dr. Rondon-Berrios obtained his MD degree at Universidad Nacional Mayor de San Marcos in Lima, Peru. He then completed Internal Medicine Residency training at University of Texas Medical Branch in Galveston, Texas followed by Nephrology Fellowship at University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania where he also received a Master of Science degree in medical education. Dr. Rondon-Berrios has authored several publications in the area of hyponatremia. He had received NIH funding to study the role of oral urea in the management of chronic hyponatremia. His current research focus on the efficacy and safety profile of desmopressin to prevent rapid correction of hyponatremia, and the neurological outcomes of profound hyponatremia (plasma sodium < 110 mmol/L).
Institution

Day 1 - Sunday April 14, 2024

Time Session
9 a.m.
10:30 a.m.
Precise Phenotyping and Treatment
SK01
HeatherReich Chairperson CanadaUniversity of Toronto, University Health Network
SebastiánJaurretche Chairperson sebastianjaurretche@hotmail.comArgentinaSanatorio Parque SA
  • Deciphering the IGAN Cell Atlas
    JulioSaez-Rodriguez Speaker julio.saez@uni-heidelberg.deGermanyHeidelberg University
  • Complement-mediated Kidney Diseases in the Era of Complement Inhibitors
    MarinaVivarelli Speaker marina.vivarelli@opbg.netItalyLaboratory of Nephrology, Bambino Gesù Children's Hospital
  • CART-T
    JonathanHogan Speaker jonathan.hogan@cabalettabio.comCabaletta Bio
  • New Targets to Reduce the Burden of Rare Kidney Diseases
    LauraMariani Speaker lmariani@umich.eduUnited StatesUniversity of Michigan
  • Q and A
Hall C4
11 a.m.
12 p.m.
Plenary Session 2: CrisprCas9 Therapy for Sickle Cell Diseases: How Do We Go from Discovery to Equitable Availability of Gene Therapy for All? (Obiageli Eunice Nnodu, Nigeria)
PL2
AgnesFogo Chairperson United States
GuillermoRosa Diez Chairperson guillermo.rosadiez@hospitalitaliano.org.arArgentinaHospital Italiano de Buenos Aires; Argentinean Society of Nephrology; Latinoamerican Society of Nephrology and Hypertension; International Society of Nephrology
  • My Story
    VictoriaGray Speaker vwright_03@yahoo.comUnited States
  • CrisprCas9 Therapy for Sickle Cell Diseases: How Do We Go from Discovery to Equitable Availability of Gene Therapy for All? Hugh de Wardener Lecture
    Obiageli EuniceNnodu Speaker oennodu@gmail.comNigeriaUniversity of Abuja
Hall A
12:15 p.m.
1:15 p.m.
Hot Debate: Should a Low Protein Diet (+/- Ketoanalogue Supplementation) Be Part of Advanced CKD Management?
LF02
CarlaAvesani Chairperson carla.avesani@ki.seSwedenKarolinska Institute
SahirKalim Chairperson skalim@mgh.harvard.eduUnited StatesHarvard Medical School/ Massachusetts General Hospital
  • Hot Debate: Should Low Protein Diet (+/- Ketoanalogue Supplementation) Be a Part of Advanced CKD Management? - PROS
    ConnieRhee Speaker crhee@mednet.ucla.eduUnited StatesUCLA
  • Hot Debate: Should Low Protein Diet (+/- Ketoanalogue Supplementation) Be a Part of Advanced CKD Management? - CONS
    SwapnilHiremath Speaker CanadaUniversity of Ottawa
Hall A
3 p.m.
4 p.m.
A Balancing Act: Your Kidneys and Electrolytes
LF1007
Angela Yee-MoonWang Chairperson SingaporeHong Kong/Singapore
ThiagoDe Azevedo Reis Chairperson thiagoreisnefro@gmail.comBrazilHospital Sírio-Libanês, São Paulo, Brazil & Fenix
  • Is Magnesium a Missing Puzzle for Vascular Calcification in CKD?
    SolaAoun Bahous Speaker sola.bahous@gmail.comLebanonLebanese American University School of Medicine
  • Should Potassium Be Restricted or Not in CKD?
    RobertoPecoits Filho Speaker United StatesArbor Research Collaborative for Health
  • Metabolic Acidosis in CKD: When to Treat? What to Target?
    MitchellRosner Speaker United StatesUniveristy of Virginia Health
  • Q and A
Hall A
Cardiorenal Syndrome: Updates in the Pathophysiology and State-of-the-Art Treatment
IK01
FelipeInserra Chairperson felipe.inserra@gmail.comArgentina
YelenaDrexler Chairperson yrd6@miami.eduUnited StatesUniversity of Miami Miller School of Medicine
  • New Insights into the Mechanisms of Kidney Injury in the CRS
    WendyMccallum Speaker wmccallum@tuftsmedicalcenter.orgUnited States
  • Novel Pharmacological Treatments of the CRS
    MarkSarnak Speaker msarnak@tuftsmedicalcenter.orgUnited StatesTufts Medical Center
  • Device-related Treatment for CRS
    ClaudioRonco Speaker cronco@goldnet.itItalyInternational Renal Research Institute of Vicenza
  • Q and A
Hall D
4:30 p.m.
5:30 p.m.
Building Competency in Nephrology Education
BKH1004
Augusto CesarSoares dos Santos Junior Chairperson BrazilHospital das Clinicas, UFMG; Fac Ciências Medicas
Li-LiHsiao Chairperson lhsiao@bwh.harvard.eduUnited StatesBrigham and Women\'s Hospital, Harvard Medical School
  • Curriculum Design to Developing Competency in Nephrology Practice
    ReneScalet Dos Santos Neto Speaker renesantosneto@gmail.comBrazilFaculdades Pequeno Principe (FPP) - Brazil
  • Developing Clinical Reasoning
    KarenWarburton Speaker KMW2G@uvahealth.orgUnited StatesUniversity of Virginia Health System
  • Assessment of Nephrology Trainees to Ensure Competence
    SolaAoun Bahous Speaker sola.bahous@gmail.comLebanonLebanese American University School of Medicine
  • Q and A
Hall C2
Salt Substitutes and HTN/CVD
IK02
ConnieRhee Chairperson crhee@mednet.ucla.eduUnited StatesUCLA
GerardoGamba Chairperson gamba@biomedicas.unam.mxMexicoUniversidad Nacional Autónoma de México
  • Potassium-based Salt Substitutes and CVD
    HoornEwout Speaker e.j.hoorn@erasmusmc.nlNetherlandsErasmus Medical Center, Rotterdam, The Netherlands
  • Strategies for Scaling the Use of Potassium-enriched Salt
    BruceNeal Speaker lclifford@georgeinstitute.org.auAustraliaThe George Institute, UNSW, Imperial College
  • Use of Salt Meters to Reduce Salt Intake
    SurasakKantachuvesiri Speaker ThailandNephrology Division, Faculty of Medicine, Ramathib
  • Q and A
Hall E

Day 2 - Monday April 15, 2024

Time Session
3 p.m.
4 p.m.
Treatment Goals for Severe Hyponatremia: A Debate on Current Guidelines Program
LF1005
MitchellRosner Chairperson United StatesUniveristy of Virginia Health
  • Overview of Hyponatremia
    Angela Yee-MoonWang Speaker SingaporeHong Kong/Singapore
  • Pro: Current Guidelines are Appropriate
    HelbertRondon-Berrios Speaker rondonberriosh@upmc.eduUnited StatesUniversity of Pittsburgh School of Medicine
  • Con: Current Guidelines are Too Conservative
    CarlosAyus Speaker carlosayus@yahoo.comUnited StatesUniversity of California Irvine
  • Discussion
Hall C3
3:45 p.m.
4:45 p.m.
Young Nephrologists Quiz-a-Thon
SPOT-18
MarinaWainstein Spotlight Chairperson ArgentinaAcademia Nacional de Medicina de Buenos Aires
Spotlight Stage 1 (exhibition hall)

Day 3 - Tuesday April 16, 2024

Time Session
9 a.m.
10 a.m.
Type 2 Diabetes in Kidney Disease: Recent Updates and Best Practices for Detection and Treatment
LF1002
DebasishBanerjee Chairperson United KingdomSt George's University Hospital NHS Foundation Tr
MegJardine Chairperson AustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia
  • Setting the Scene
    MegJardine Speaker AustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia
  • DM and CKD: Which Treatment Should I Use for Different Populations?
    KatherineTuttle Speaker United StatesUniversity of Washington School of Medicine, Division of Nephrology
  • How to Design Studies on Answering Unanswered Questions
    VladoPerkovic Speaker AustraliaUniversity of New South Wales, Sydney, Australia
  • The Effect of SGLT2 Inhibitors in Patients with Chronic Kidney Disease, With or Without Type 2 Diabetes
    DavidWheeler Speaker United KingdomUniversity College London
  • Q and A
Hall C4
Hi Aldo, What's New? Advances in Aldosterone in Health and Disease
IK04
CarlosSchreck Chairperson carlos.schreck@gmail.comArgentinaHospital Italiano de Buenos Aires- Nephrology
KellyHaughton Chairperson kidneydoctorpanama@gmail.comPanamaSLANH, Panama
  • Why Are Fewer Than I% Of Hypertensive Patients Ever Screened For Primary Aldosteronism?
    John Funder Speaker John.Funder@hudson.org.auAustraliaThe Hudson Institute of Medical Research Clayton 3168 Victoria Australia; Monash University, Clayton 3600 Victoria Australia
  • Aldosterone and Disease
    JordanaCohen Speaker jco@pennmedicine.upenn.eduUnited StatesUniversity of Pennsylvania
  • New Trials Using Aldosterone Synthese Blockade
    MichelAzizi Speaker michel.azizi@aphp.frFranceUniversité Paris Cité, Hypertension department, Hô
  • Targeting MR for Heart and Kidney Protection
    HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
  • Q and A
Hall E
9 a.m.
10:30 a.m.
Clinical Management of Glomerulonephritis (GN)
SK06
Juan ManuelMejia Vilet Chairperson jmmejia@hotmail.comMexicoInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
ValeriaAlberton Chairperson vgalberton@gmail.comArgentinaHospital Fernandez/ Hospital El Cruce
  • Updates on IgAN Management
    HernánTrimarchi Speaker ArgentinaHOSPITAL BRITÁNICO DE BUENOS AIRES
  • Membranous GN Classification and Management
    PierreRonco Speaker FranceHôpital Tenon
  • MPGN Updates
    SanjeevSethi Speaker United StatesMayo Clinic
  • Managing Vasculitis
    RobertaFenoglio Speaker roberta.fenoglio@unito.itItalyOspedale San Giovanni Bosco
  • Q and A
Hall A
11 a.m.
12:15 p.m.
Plenary Session 4: Insights into SGLT2 Inhibitors: A Story of Discovery (Ele Ferrannini, Italy)
PL4
AlessiaFornoni Chairperson United StatesUniversity of Miami
LizLightstone Chairperson United KingdomImperial College London
MasaomiNangaku Chairperson Japan
  • Acceptance Speech: Bywaters Award
    MotokoYanagita Speaker JapanKyoto University
  • Insights into SGLT2 Inhibitors: A Story of Discovery. Donald Seldin Lecture
    EleFerrannini Speaker eleferrannini@gmail.comItalyUniversity of Pisa
  • ELP2 Graduation
    MasaomiNangaku Speaker Japan
Hall A
12:30 p.m.
1:30 p.m.
Hot Debate in CKD Hypertension Management: Targeting Systolic BP Below 120?
IK05
MarceloOrías Chairperson marcelo.orias@gmail.comArgentina
MarkSarnak Chairperson msarnak@tuftsmedicalcenter.orgUnited StatesTufts Medical Center
  • Hot Debate in CKD Hypertension Management: Targeting Systolic BP Below 120? - PROS
    TaraChang Speaker tichang@stanford.eduUnited StatesStanford University
  • Hot Debate in CKD Hypertension Management: Targeting Systolic BP Below 120? - CONS
    JordanaCohen Speaker jco@pennmedicine.upenn.eduUnited StatesUniversity of Pennsylvania
Hall A

Pre-Congress - Saturday April 13, 2024

Time Session
4:30 p.m.
6 p.m.
WCN'24 Opening Ceremony and Plenary Session 1: The Origin of the Universe (Daniel de Florian, Argentina)
OCPL1
  • ISN President's Address
    MasaomiNangaku Speaker Japan
  • Tribute to Stewart Cameron
  • Welcome by WHO Director of Non-Communicable Diseases Dr Bente Mikkelsen
  • Welcome by Dr. Marina Papaginovic, SAN President; Dr. Guillermo Rosa Diez, WCN Local Organising Group Chair; and Dr. Jorge Rico, SLANH President and WCN Local Organizing Group co-Chair
    GuillermoRosa Diez Speaker guillermo.rosadiez@hospitalitaliano.org.arArgentinaHospital Italiano de Buenos Aires; Argentinean Society of Nephrology; Latinoamerican Society of Nephrology and Hypertension; International Society of Nephrology
    JorgeRico Speaker jorgericof@yahoo.comColombia
    MariaPapaginovic Leiva Speaker drapapaginovicleiva@gmail.comArgentina
  • Welcome by Minister of Health for Buenos Aries Dr Fern
  • Welcome by SPWG Chair Alessia Fornoni
    AlessiaFornoni Speaker United StatesUniversity of Miami
  • The Origin of the Universe
    DanielDe Florian Speaker deflo@unsam.edu.arArgentinaUniversidad Nacional de San Martin
  • Acceptance Speech: Hamburger Award
    AdeeraLevin Speaker CanadaUniversity of British Columbia and Providence Health Care
Hall A